{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:40:47Z","timestamp":1773877247812,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":269,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100468","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T07:23:18Z","timestamp":1633159398000},"page":"100468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Immunotherapy in multiple myeloma"],"prefix":"10.1016","volume":"29","author":[{"given":"Yamna","family":"Jadoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustaqeem A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ctarc.2021.100468_bib0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100468_bib0002","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100468_bib0003","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2141.1998.00525.x","article-title":"B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors","volume":"100","author":"Rawstron","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100468_bib0004","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2249.2001.01582.x","article-title":"Deregulated cytokine network and defective Th1 immune response in multiple myeloma","volume":"125","author":"Frassanito","year":"2001","journal-title":"Clin. Exp. Immunol."},{"issue":"10","key":"10.1016\/j.ctarc.2021.100468_bib0005","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100468_bib0006","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","volume":"24","author":"Jurisic","year":"2007","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100468_bib0007","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"issue":"2722","key":"10.1016\/j.ctarc.2021.100468_bib0008","article-title":"CD38: a Target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100468_bib0009","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"Supplement_1","key":"10.1016\/j.ctarc.2021.100468_bib0010","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1182\/blood-2019-128592","article-title":"Daratumumab inhibits AML metabolic capacity and tumor growth through inhibition of CD38 mediated mitochondrial transfer from bone marrow stromal cells to blasts in the leukemic microenvironment","volume":"134","author":"Mistry","year":"2019","journal-title":"Blood"},{"issue":"10027","key":"10.1016\/j.ctarc.2021.100468_bib0011","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100468_bib0012","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100468_bib0013","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"10245","key":"10.1016\/j.ctarc.2021.100468_bib0014","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"The Lancet"},{"issue":"22","key":"10.1016\/j.ctarc.2021.100468_bib0015","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"New Engl. J. Med."},{"issue":"10192","key":"10.1016\/j.ctarc.2021.100468_bib0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"The Lancet"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2021.100468_bib0017","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1200\/jco.2014.32.15_suppl.8532","article-title":"A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma","volume":"32","author":"Martin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100468_bib0018","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2019.37.15_suppl.8004","article-title":"A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"37","author":"Richardson","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100468_bib0019","series-title":"EHA25 Annual Congress","article-title":"Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma (IKEMA): interim analysis of a phase 3, randomized, open-label study","author":"Moreau","year":"2020"},{"issue":"1 Supplement","key":"10.1016\/j.ctarc.2021.100468_bib0020","doi-asserted-by":"crossref","first-page":"224.20","DOI":"10.4049\/jimmunol.198.Supp.224.20","article-title":"TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion","volume":"198","author":"Smithson","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.ctarc.2021.100468_bib0021","doi-asserted-by":"crossref","first-page":"8539","DOI":"10.1200\/JCO.2020.38.15_suppl.8539","article-title":"A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed\/refractory multiple myeloma (RRMM): preliminary results","volume":"38","author":"Krishnan","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"16 Supplement","key":"10.1016\/j.ctarc.2021.100468_bib0022","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/1538-7445.AM2020-2266","article-title":"Abstract 2266: SAR442085, a next generation anti-CD38 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma","volume":"80","author":"Virone-Oddos","year":"2020","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100468_bib0023","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for Multiple Myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers,"},{"key":"10.1016\/j.ctarc.2021.100468_bib0024","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100468_bib0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1535-7163.MCT-19-1079","article-title":"Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding","volume":"19","author":"Puro","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"13 Supplement","key":"10.1016\/j.ctarc.2021.100468_bib0026","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1538-7445.AM2018-2709","article-title":"Abstract 2709: TTI-622 (SIRP\u03b1-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with antitumor antibodies in both hematologic and solid tumor models","volume":"78","author":"Lin","year":"2018","journal-title":"Cancer Res."},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2021.100468_bib0027","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136607","article-title":"Investigational CD47-Blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study","volume":"136","author":"Patel","year":"2020","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctarc.2021.100468_bib0028","doi-asserted-by":"crossref","first-page":"16248","DOI":"10.18632\/oncotarget.24575","article-title":"Signaling lymphocytic activation molecules Slam and cancers: friends or foes?","volume":"9","author":"Fouquet","year":"2018","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2021.100468_bib0029","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1200\/jco.2015.33.15_suppl.8508","article-title":"ELOQUENT-2: a phase III, randomized, open-label study of lenalidomide (Len)\/dexamethasone (dex) with\/without elotuzumab (Elo) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"33","author":"Lonial","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ctarc.2021.100468_bib0030","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"New Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ctarc.2021.100468_bib0031","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ctarc.2021.100468_bib0032","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100468_bib0033","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4049\/jimmunol.1302197","article-title":"Cutting Edge: DNAX Accessory Molecule 1\u2013Deficient CD8+T Cells Display Immunological Synapse Defects That Impair Antitumor Immunity","volume":"192","author":"Ramsbottom","year":"2014","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100468_bib0034","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ctarc.2021.100468_bib0035","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-021-02921-8","article-title":"COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade","author":"Hansen","year":"2021","journal-title":"Cancer Immunol., Immunother."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100468_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"10200","key":"10.1016\/j.ctarc.2021.100468_bib0037","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"The Lancet,"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100468_bib0038","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int. Immunol."},{"issue":"6","key":"10.1016\/j.ctarc.2021.100468_bib0039","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"25","key":"10.1016\/j.ctarc.2021.100468_bib0040","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100468_bib0041","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100468_bib0042","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk Res."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100468_bib0043","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T Cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100468_bib0044","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody\u2013drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100468_bib0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"The Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100468_bib0046","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100468_bib0047","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.ctarc.2021.100468_bib0048","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","article-title":"A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma","volume":"34","author":"Xing","year":"2020","journal-title":"Leukemia"},{"issue":"13 Supplement","key":"10.1016\/j.ctarc.2021.100468_bib0049","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/1538-7445.AM2019-2384","article-title":"Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma","volume":"79","author":"Willert","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100468_bib0050","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted Therapy With Immunoconjugates for Multiple Myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front Immunol."},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2021.100468_bib0051","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136928","article-title":"TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells","volume":"136","author":"Bruins","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100468_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162472","article-title":"Targeting Attenuated Interferon-\u03b1 to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity","volume":"11","author":"Pogue","year":"2016","journal-title":"PLoS ONE"},{"issue":"Suppl 3","key":"10.1016\/j.ctarc.2021.100468_bib0053","first-page":"A218","article-title":"357\u2005TAK-573, an anti-CD38\u2013attenuated interferon alpha (IFN\u03b1) fusion protein (Attenukine\u2122), has demonstrated IFN\u03b1 receptor (IFNAR) pathway modulation in patients with relapsed\/refractory multiple myeloma","volume":"8","author":"Collins","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"16 Supplement","key":"10.1016\/j.ctarc.2021.100468_bib0054","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1538-7445.AM2020-5546","volume":"80","author":"Hara","year":"2020","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ctarc.2021.100468_bib0055","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.clml.2019.09.192","article-title":"TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFN\u03b1) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo","volume":"19","author":"Fatholahi","year":"2019","journal-title":"Clin. Lymphoma, Myeloma Leukemia,"},{"issue":"102","key":"10.1016\/j.ctarc.2021.100468_bib0056","doi-asserted-by":"crossref","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2021.100468_bib0057","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-139192","article-title":"REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100468_bib0058","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front Immunol."},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2021.100468_bib0059","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-139893","article-title":"Initial results of a phase I study of TNB-383B, a BCMA x CD3 bispecific T-Cell redirecting antibody, in relapsed\/refractory multiple myeloma","volume":"136","author":"Rodriguez","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2021.100468_bib0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-133355","article-title":"Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B-Cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Lesokhin","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100468_bib0061","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti\u2013B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2021.100468_bib0062","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 first in human (FIH) study of AMG 701, an Anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100468_bib0063","article-title":"Interim results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) 2+1 T-cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","author":"Costa","year":"2020","journal-title":"EHA 25 Annual Congress"},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2021.100468_bib0064","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-138831","article-title":"Updated phase 1 results of teclistamab, a B-Cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2021.100468_bib0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136985","article-title":"Initial clinical activity and safety of BFCR4350A, a FcRH5\/CD3 T-Cell-engaging bispecific antibody, in relapsed\/refractory multiple myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2021.100468_bib0066","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-133873","article-title":"A Phase 1, first-in-human study of Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and\/or refractory multiple myeloma (RRMM)","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2021.100468_bib0067","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2018-99-113921","article-title":"Preclinical and nonclinical characterization of HPN217: a Tri-Specific T Cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma","volume":"132","author":"Law","year":"2018","journal-title":"Blood"},{"issue":"16 Supplement","key":"10.1016\/j.ctarc.2021.100468_bib0068","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1158\/1538-7445.AM2020-5641","article-title":"Abstract 5641: CD28 expression on multiple myeloma cells enhances the cytotoxic activity of CD38\/CD28xCD3 trispecific T cell engager","volume":"80","author":"El-Murr","year":"2020","journal-title":"Cancer Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:23:57Z","timestamp":1762842237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221001647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":68,"alternative-id":["S2468294221001647"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100468","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100468"}}